NCT04386096

Brief Summary

Medication is an efficacious treatment strategy for adolescents with attention-deficit/hyperactivity disorder (ADHD), however use significantly declines during adolescence when the consequences of ADHD are most severe (e.g. dropping out of school, delinquency, etc.). The Unified Theory of Behavior Change (UTBC) has been proposed as a conceptual model to explain the mechanism underlying ADHD medication adherence and to guide the development of interventions to improve the continuity of treatment. The UTBC is a well-established and empirically tested model that identifies factors that influence an individual's intention to perform a behavior as well as factors that influence whether a behavior is actually carried out. Indeed, the research team's preliminary data support the relevance of pre-intention factors and implementation factors for medication continuity among adolescents with ADHD. Currently, no evidence-based interventions target medication continuity for adolescents with ADHD. The objective of this study is to test a multi-component intervention that systematically identifies and targets aspects of the UTBC model most relevant for each adolescent with poor ADHD medication continuity. The central hypothesis is that the tailored intervention will support ADHD medication continuity. The study will objectively test the central hypothesis by conducting a randomized controlled trial among adolescents with poor medication continuity to test whether the intervention engages the mechanism underlying medication continuity and improves outcomes.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jun 2020

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 5, 2020

Completed
8 days until next milestone

First Posted

Study publicly available on registry

May 13, 2020

Completed
19 days until next milestone

Study Start

First participant enrolled

June 1, 2020

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 16, 2021

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 24, 2021

Completed
10 months until next milestone

Results Posted

Study results publicly available

March 21, 2022

Completed
Last Updated

March 21, 2022

Status Verified

February 1, 2022

Enrollment Period

9 months

First QC Date

May 5, 2020

Results QC Date

October 7, 2021

Last Update Submit

February 22, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Proportion of Days Covered With Medicine

    This will be calculated based pharmacy dispensing records

    An average of 4 months

Secondary Outcomes (7)

  • Fidelity to Intended Use of Intervention Components

    An average of 4 months

  • Change in Pre-intention Factors of Unified Theory of Behavior Change

    At baseline and approximately 4 months later

  • Change in Intention to Take/Give ADHD Medicine Regularly

    At baseline and approximately 4 months later

  • Change in Adolescent-report of Medication Barriers

    At baseline and approximately 4 months later

  • Change in Parent-report of Medication Barriers

    At baseline and approximately 4 months later

  • +2 more secondary outcomes

Study Arms (2)

Mehealth for ADHD software with medication continuity tools

EXPERIMENTAL
Other: Mehealth for ADHD software with medication continuity tools

Mehealth for ADHD software with no medication continuity tools

ACTIVE COMPARATOR
Other: Mehealth for ADHD software with no medication continuity tools

Interventions

Medication continuity tools integrated within the mehealth for ADHD software will assess factors influencing medication continuity for each adolescent and recommend tools to address relevant factors. Tools include 1) a system to track outcomes and resolve uncertainty about the need for and/or benefit from medicine, 2) a module to address stigma, 3) a module to help manage side effects, and 4) reminders to take medicine and/or request refills.

Mehealth for ADHD software with medication continuity tools

The mehealth for ADHD software has multiple functionalities including 1) online training regarding the American Academy of Pediatrics (AAP) ADHD guidelines; 2) an ADHD workflow wizard that guides pediatricians through the creation of an efficient office workflow to deliver quality ADHD care; 3) online collection of parent- and teacher-report ADHD rating scales for the assessment of ADHD as well as monitoring response to medication treatment; 4) integrated algorithms that automatically score rating scales in real time and provide pediatricians with assessment and treatment reports as well as immediate warnings; 5) an online pediatrician "report card"; and 6) a Plan-Do-Study-Act wizard that allows pediatricians to select a practice behavior to improve based on their report card and guides them through the creation of small tests of change to improve their office systems.

Mehealth for ADHD software with no medication continuity tools

Eligibility Criteria

Age11 Years - 15 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • First prescribed ADHD medicine more than one year prior to enrollment
  • Treated by pediatrician at practice participating in study
  • Filled at least one prescription for a stimulant medication in the past year

You may not qualify if:

  • More than 80% of days covered with medicine over past one year
  • Poor understanding level: The participant and parent cannot understand or follow instructions given in the study.
  • Do not have reliable access to the internet at their home or another location.
  • Parent will not permit their child to access the internet for study related activities
  • Are not able or willing to send or receive text messages for study related activities

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, 45229-3039, United States

Location

MeSH Terms

Conditions

Attention Deficit Disorder with HyperactivityMedication Adherence

Condition Hierarchy (Ancestors)

Attention Deficit and Disruptive Behavior DisordersNeurodevelopmental DisordersMental DisordersPatient CompliancePatient Acceptance of Health CareTreatment Adherence and ComplianceHealth BehaviorBehavior

Results Point of Contact

Title
Dr. William B. Brinkman
Organization
Cincinnati Children's

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 5, 2020

First Posted

May 13, 2020

Study Start

June 1, 2020

Primary Completion

February 16, 2021

Study Completion

May 24, 2021

Last Updated

March 21, 2022

Results First Posted

March 21, 2022

Record last verified: 2022-02

Data Sharing

IPD Sharing
Will share

Locations